Based on the results of the OlympiA trial, the use of adjuvant olaparib in high-risk, HER2-negative early breast cancer is recommended in several guidelines and is approved by regulatory bodies in numerous countries, including Canada [6,8,27,28,29]. Here, ERBB2 is linked to breast carcinoma.